Dermatologic Manifestations of Viral Hemorrhagic Fevers
- Author: Arash Michael Saemi, MD; Chief Editor: Dirk M Elston, MD more...
Background
Viral hemorrhagic fevers (VHFs) are a group of etiologically diverse viral diseases unified by common underlying pathophysiology. These febrile diseases result from infection by viruses from 4 viral families: Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae.
The viruses in the 4 families are all RNA viruses. All share the feature of having a lipid envelope. Survival and perpetuation of the viruses is dependent on an animal host known as a natural reservoir; humans are not the natural reservoir. With the exception of a vaccine for yellow fever and ribavirin, which is used as a drug treatment for some arenaviral infections, no cures or drug treatments for viral hemorrhagic fever exist. Only supportive treatment is possible.
Not all viruses in these families cause viral hemorrhagic fever. Viral hemorrhagic fevers share certain clinical manifestations, regardless of the virus that causes the disease. However, different viruses can cause a range of various clinical problems in addition to viral hemorrhagic fever. Common clinical manifestations of viral hemorrhagic fever are increased capillary permeability, leukopenia, and thrombocytopenia. Viral hemorrhagic fever is manifested by sudden onset, fever, headache, generalized myalgia, backache, petechiae, conjunctivitis, and severe prostration. Various hemorrhagic symptoms follow, ultimately resulting in focal inflammatory reaction and necrosis with leukocytosis.
Although the viruses are distributed all over the world, they have a higher occurrence in tropical areas, such as South America, Africa, and the Pacific Islands. They have a higher likelihood of importation because of increased travel and scientific research involving the use of imported tropical animals, which often serve as intermediate hosts. The viruses are transmitted by 2 main categories of natural reservoirs: arthropods and rodents. Arenaviruses and Hantavirus (a Bunyavirus) are primarily rodent-borne, whereas flaviviruses, as well as nairoviruses and phleboviruses (both bunyaviruses), are arthropod-borne.
Transmission occurs mainly by means of contact with the following: natural reservoirs (eg, mosquito bites, rodent bites); reservoir excretions, secretions, or blood; aerosolized particles contaminated by reservoir secretions, excretions, or blood; or intermediate hosts (eg, monkeys, livestock) or their excretions, secretions, or blood. Person-to-person transmission and nosocomial transmission also occur. Nosocomial outbreaks are not uncommon in developing countries, where safe infectious disease practices have not been implemented and supplies are in shortage.
Also see the Medscape Reference articles CBRNE - Viral Hemorrhagic Fevers and Viral Hemorrhagic Fevers (Pediatrics version).
Pathophysiology
The main common underlying pathophysiologic feature of viral hemorrhagic fevers is that the vascular bed is attacked, with resultant microvascular damage and changes in vascular permeability. However, specific pathophysiologic findings can vary depending on the virus family and the species involved.
In general, an initial febrile illness is followed by hemorrhaging into the skin and the mucous membranes; hemorrhagic rashes; and hemorrhages from body orifices, especially gastrointestinal and genitourinary bleeding. Lassa fever, although fatal, is not characterized by significant bleeding. Other clinical findings include thrombocytopenia and leukocytopenia.
Epidemiology
Frequency
United States
Most of the natural reservoirs of these viruses live in tropical areas. Hence, the virus does not typically infect persons in the United States. Random cases of infection occur as a result of the importation of viruses by travelers or the importation of scientific research animal subjects. Several cases of infection resulting in Hantavirus pulmonary syndrome (HPS), however, have been reported across the United States.[1]
International
Table 1. Geographic Distribution of Viral Hemorrhagic Fevers (Open Table in a new window)
| Virus Family and Genus | Type of Hemorrhagic Fever | Geographic Distribution |
| Arenaviridae Guanarito Junin Machupo Lassa Sabia | Venezuelan Argentinian Bolivian Lassa (West Africa) Brazilian or Sao Paulo | Venezuela Argentina Bolivia West Africa Brazil |
| Bunyaviridae Nairovirus Phlebovirus Hantaan virus | Crimean-Congo Rift Valley Korean HPS | Crimea, Central Africa, South Africa, Iraq, Pakistan Africa, Egypt Korea, Eastern Europe, Russia, Scandinavia North, Central, and South America |
| Flaviviridae Flavivirus Flavivirus Flavivirus Flavivirus | Yellow Dengue Chikungunya Omsk | Tropical Africa, South America Entire tropical zone India, Southeast Asia Siberia |
| Filoviridae Marburg Ebola | Marburg Ebola | Africa Africa |
Mortality/Morbidity
Children can develop dengue hemorrhagic shock syndrome (DHSS), a complication with a mortality rate of 4-12%.
Table 2. Viral Hemorrhagic Fever Mortality Rates (Open Table in a new window)
| Virus Family and Type of VHF | Mortality Rate, % |
| Arenaviridae Argentinian and Bolivian Lassa (West African) Venezuelan and Sao Paulo | 10-30 30-40 33 |
| Bunyaviridae Korean and Seoul Rift Valley Congo-Crimean HPS | 5-15 1 10-50 15-50 |
| Flaviviridae Yellow Dengue | < 1 5 |
| Filoviridae Marburg Ebola | 23-25 25-100 |
Race
No race is known to be more vulnerable than another to RNA viral infection. Geography is a determining factor.
Sex
Neither sex is known to be more or less vulnerable to RNA viral infection.
Age
Age plays a role in increasing the vulnerability to infection in only 2 circumstances, as follows:
- First, young and elderly persons are more susceptible because of their weaker immune systems.
- Second, adults are more susceptible if they work in settings in which the exposure risk is increased (eg, clinics or hospitals, agrarian settings).
Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. Apr 2008;78(1):162-9. [Medline].
Southern PJ. Arenaviridae: the viruses and their replication. In: Fields BN, Knipe DN, Howley PM, et al, eds. Fields Virology. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1996:1505-19.
Peters CJ, Linthicum KJ. Rift valley fever. In: Handbook of Zoonoses. Boca Raton, Fla: CRC Press; 1994:129-43.
Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, Njenga MK. Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg. Mar 2010;82(3):371-5. [Medline].
Seo JH, Park KH, Lim JY, Youn HS. Hemorrhagic fever with renal syndrome (HFRS, Korean hemorrhagic fever). Pediatr Nephrol. Jan 2007;22(1):156-7. [Medline].
Feldmann H. Marburg hemorrhagic fever--the forgotten cousin strikes. N Engl J Med. Aug 31 2006;355(9):866-9. [Medline].
Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis. Oct 2006;19(5):429-36. [Medline].
No Authors Listed. Dengue haemorrhagic fever: early recognition, diagnosis and hospital management--an audiovisual guide for health-care workers responding to outbreaks. Wkly Epidemiol Rec. Sep 22 2006;81(38):362-3. [Medline].
Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res. Apr 2008;78(1):150-61. [Medline].
Noisakran S, Perng GC. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp Biol Med (Maywood). Apr 2008;233(4):401-8. [Medline].
Kurosaki Y, Grolla A, Fukuma A, Feldmann H, Yasuda J. Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method. J Clin Microbiol. Jul 2010;48(7):2330-6. [Medline].
Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. Apr 2008;78(1):125-31. [Medline].
Ghosh D, Basu A. Present perspectives on flaviviral chemotherapy. Drug Discov Today. Jul 2008;13(13-14):619-24. [Medline].
Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Ströher U, Hensley LE, Grolla A, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol. Oct 2006;80(19):9659-66. [Medline].
Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. Nov 2006;13(11):1267-77. [Medline].
Kothari VM, Karnad DR, Bichile LS. Tropical infections in the ICU. J Assoc Physicians India. Apr 2006;54:291-8. [Medline].
Collier L, Oxford J. Human Virology. 2nd ed. Oxford, England: Oxford University Press; 2000:171-97.
Craighead JE, John E. Pathology and Pathogenesis of Human Viral Disease. San Diego, Calif: Academic Press; 2000:277-93.
Fields BN, Knipe DM. Fundamental Virology. 2nd ed. New York, NY: Raven Press; 1991:19-24.
Gear JH. Handbook of Viral and Rickettsial Hemorrhagic Fevers. Boca Raton, Fla: CRC Press; 1988:5-240.
Medical Economics Staff. Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics; 2001:1547, 2932.
Special Pathogens Branch. Marburg hemorrhagic fever, imported case - Netherlands ex Uganda, July 2008. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/ncidod/dvrd/spb.
Zuckerman AJ, Banatvala JE, Pattison JR. Principles and Practice of Clinical Virology. 4th ed. New York, NY: John Wiley & Sons; 2000:485-581.
| Virus Family and Genus | Type of Hemorrhagic Fever | Geographic Distribution |
| Arenaviridae Guanarito Junin Machupo Lassa Sabia | Venezuelan Argentinian Bolivian Lassa (West Africa) Brazilian or Sao Paulo | Venezuela Argentina Bolivia West Africa Brazil |
| Bunyaviridae Nairovirus Phlebovirus Hantaan virus | Crimean-Congo Rift Valley Korean HPS | Crimea, Central Africa, South Africa, Iraq, Pakistan Africa, Egypt Korea, Eastern Europe, Russia, Scandinavia North, Central, and South America |
| Flaviviridae Flavivirus Flavivirus Flavivirus Flavivirus | Yellow Dengue Chikungunya Omsk | Tropical Africa, South America Entire tropical zone India, Southeast Asia Siberia |
| Filoviridae Marburg Ebola | Marburg Ebola | Africa Africa |
| Virus Family and Type of VHF | Mortality Rate, % |
| Arenaviridae Argentinian and Bolivian Lassa (West African) Venezuelan and Sao Paulo | 10-30 30-40 33 |
| Bunyaviridae Korean and Seoul Rift Valley Congo-Crimean HPS | 5-15 1 10-50 15-50 |
| Flaviviridae Yellow Dengue | < 1 5 |
| Filoviridae Marburg Ebola | 23-25 25-100 |

